2月28日，太美医疗科技（02576）发布公告，预计2024财年将录得不超过2.2亿元的亏损净额，相较于2023年财年的亏损净额约为3.56亿元，预计亏损净额减少将不少于38%。公司表示，此次亏损减少主要归因于聚焦核心竞争力产品、提升管理效率，从而提高整体毛利率，同时销售开支和研发开支也有所减少。
此外，公司还提到经调整亏损净额（非国际财务报告准则计量）预计将不超过6000万元，而截至2023年财年的经调整亏损净额约为3.17亿元，预计减少将不少于81%。虽然公司相信经调整亏损净额能够提供有用信息，但提醒股东和投资者不应将其视为替代国际财务报告准则下的经营业绩或财务状况的分析工具。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.